Oxford Biomedica Joins Consortium to Develop ChAdOx1 nCov-19 for COVID-19

 Oxford Biomedica Joins Consortium to Develop ChAdOx1 nCov-19 for COVID-19

Oxford Biomedica Joins Consortium to Develop ChAdOx1 nCov-19 for COVID-19

Shots:

  • Oxford Biomedica has joined the consortium, which is led by the Jenner Institute, University of Oxford and also includes the VMIC, Pall Life Sciences, Cobra Biologics, and Halix BV to rapidly develop, scale-up and manufacture a vaccine (ChAdOx1 nCov-19) against COVID-19
  • The ChAdOx1 nCOV-19 vaccine is anticipated to be the UK’s first COVID-19 vaccine in clinical studies to be initiated in later Apr’2020. The consortium has recruited individuals aged 18-55yrs. from the Thames Valley area in the UK to evaluate the safety and efficacy of the vaccine
  • Oxford Biomedica will allow the consortium access to its large scale GMP manufacturing facilities for viral vectors, including its new Oxbox facility. ChAdOx1 is based on adenoviral vector technology and has demonstrated positive results in pre/ clinical studies conducted to date

Click here to­ read full press release/ article | Ref: Oxford Biomedica | Image: The Pharma Letter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post